JAZZ•benzinga•
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
Summary
CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 6, 2024 by benzinga